Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 0 | 0 | 22 | 21 | 22 |
| Gross Profit | N/A | N/A | 22 | 21 | 22 |
| Operating Expenses | 71,774 | 71,431 | 69,526 | 85,130 | 63,018 |
| Operating Income | -71,774 | -71,431 | -69,504 | -85,109 | -62,996 |
| Interest Expense | 100 | 0 | 0 | 0 | 0 |
| Other Income | 5,581 | 5,073 | 4,504 | -669 | 709 |
| Pre-tax Income | -66,293 | -66,358 | -65,000 | -85,778 | -62,287 |
| Net Income Continuous | -66,293 | -66,358 | -65,000 | -85,778 | -62,287 |
| Net Income | $-66,293 | $-66,358 | $-65,000 | $-85,778 | $-62,287 |
| EPS Basic Total Ops | -0.32 | -0.35 | -0.38 | -0.49 | -0.37 |
| EPS Basic Continuous Ops | -0.32 | -0.35 | -0.38 | -0.48 | -0.37 |
| EPS Diluted Total Ops | -0.32 | -0.35 | -0.38 | -0.49 | -0.37 |
| EPS Diluted Continuous Ops | -0.32 | -0.35 | -0.38 | -0.48 | -0.37 |
| EPS Diluted Before Non-Recurring Items | -0.27 | -0.32 | -0.38 | N/A | N/A |
| EBITDA(a) | $-70,266 | $-69,988 | $-68,746 | $-84,931 | $-62,368 |